Importantly, a C3 inhibitor aimed at sites of complement activation is presently undergoing phase 2 clinical trials for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and renal disease [78]. The gene discussed is C3; the disease is kidney disorder.